Antibody Information
General Information of This Antibody (ID: ANTI0ZPGYS)
| Antibody Name | Anti-GPRC5D antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | GPRC5D |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Vemzatatug vedotin [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: signed ICF; age ≥18; ECOG 0-1; life expectancy ≥6 months; adequate hematologic/organ function (specific laboratory thresholds to be confirmed per protocol).
|
||||
| Administration Dosage |
LM-305 Dose Escalation
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05647512 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
|
||||
| Primary Endpoint |
Primary safety endpoints include dose-limiting toxicity (DLT) assessment during Cycle 1 (21-day cycle) and comprehensive AE/SAE monitoring from ICF signing until 28 days post-EOT or alternative anticancer therapy initiation to evaluate LM-305 safety profile.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
The inhibitory activity of LM-305 against cancer cell growth was evaluated in Multiple myeloma CDX model in vivo. The dose of LM-305 was 3 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.10-0.30 nM
|
High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.R cells | CVCL_8794 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.10-0.30 nM
|
High GPRC5D expression (GPRC5D+++) | ||
| Method Description |
LM-305 was evaluated in vitro for its cytotoxic activity against a panel of multiple myeloma cell lines. LM-305 was co-cultured with multiple myeloma cells.
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
References